WO2023016651A1 - Fourniture d'un signal électrique en correspondance avec une fréquence de résonance d'un matériau génétique - Google Patents

Fourniture d'un signal électrique en correspondance avec une fréquence de résonance d'un matériau génétique Download PDF

Info

Publication number
WO2023016651A1
WO2023016651A1 PCT/EP2021/072537 EP2021072537W WO2023016651A1 WO 2023016651 A1 WO2023016651 A1 WO 2023016651A1 EP 2021072537 W EP2021072537 W EP 2021072537W WO 2023016651 A1 WO2023016651 A1 WO 2023016651A1
Authority
WO
WIPO (PCT)
Prior art keywords
genetic material
resonant frequency
shifted
frequency
resonant frequencies
Prior art date
Application number
PCT/EP2021/072537
Other languages
English (en)
Inventor
Marc Vancraeyenest
Original Assignee
Azyro Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azyro Sa filed Critical Azyro Sa
Priority to PCT/EP2021/072537 priority Critical patent/WO2023016651A1/fr
Publication of WO2023016651A1 publication Critical patent/WO2023016651A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/3603—Control systems
    • A61N1/36034—Control systems specified by the stimulation parameters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0472—Structure-related aspects
    • A61N1/0476—Array electrodes (including any electrode arrangement with more than one electrode for at least one of the polarities)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0472—Structure-related aspects
    • A61N1/0484—Garment electrodes worn by the patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy

Definitions

  • the present invention relates to electro-medicine, and in particular to a method, device and/or system and computer program for providing an electrical signal and/or determining characteristics of an electrical signal in correspondence with a resonant frequency, frequency range and/or frequency domain of genetic material.
  • genetic material of an organism consists of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
  • DNA is a molecule comprising a pair of strands that are held tightly together and coil around each other forming the shape of a double helix, carrying genetic instructions for the development, functioning, growth and reproduction of organisms and viruses.
  • a DNA strand is made of units (or grains), composed of a sugar and a base. The grains are connected by phosphorus bridges (P-bonds), while complementary bases, forming base-pairs, in different strands are connected by hydrogen bonds (H-bonds).
  • RNA is a single-stranded molecule, wherein the single strand Is folded onto Itself, and configured to code, decode, regulate and express genes.
  • DNA may be regarded as a dipole antenna or vertical or electrical antenna detecting electrical signals and resonances In a specific frequency range. Rolled-up as around histones, before forming chromosomes, DNA may react as an electrical choke.
  • diseases particularly if they are triggered by pathogens, such as bacteria, parasites, fungi, viruses, etc., in the human or animal body are based at least in part on the above structures, such as proteins, DNA, cells, etc., and/or electrical mechanisms, such as model able electrical behavior, they are likely to be subject to influence them by electrical processes.
  • pathogens such as bacteria, parasites, fungi, viruses, etc.
  • US 2007/0128590 A1 describes a method for determining therapeutic resonant frequencies of electromagnetic radiation for treating an animal or human infected with a disease caused by a pathogen, wherein said pathogen comprises a genomic material, the genomic material being surrounded by a medium.
  • the method comprises providing a frequency-emitting device; determining a velocity of the electromagnetic radiation through the medium surrounding the genomic material; determining the length of the genomic material; determining a first therapeutic resonant frequency to influence the genomic material in a first electromagnetic frequency range, by dividing the velocity of the electromagnetic radiation through the medium surrounding the genomic material by the length of the genomic material; dividing or multiplying the first therapeutic resonant frequency by a factor of a power of two, to obtain a second therapeutic resonant frequency to influence said genomic material, wherein the second therapeutic resonant frequency is in an electromagnetic frequency range capable of being emitted by the frequency-emitting device; programming the frequencyemitting device to emit the first, or the second resonant frequency; and treating the animal or human with the programmed resonant frequency intended to influence said genomic material, thereby rendering a therapeutic or desirable effect in the animal or human.
  • the method comprises the step of receiving length information data associated with a wavelength of the genetic material. Further, the method comprises the step of determining a basic resonant frequency of the genetic material by dividing a velocity through a tissue or medium surrounding the genetic material by the wavelength of the genetic material. The method further comprises the step of performing a multi-stage shift on the basic resonant frequency to an operable frequency range that can be output by the medical treatment device by applying multiple multiplication or division operations, i.e. multiple stages of multiplication or division operations, on the basic resonant frequency using a number of factors different to each other. Further, the method comprises the step of generating a driver signal for providing the electrical signal based on one or more shifted resonant frequencies determined to be in the operable frequency range.
  • a frequency, frequency range and/or frequency domain i.e. a frequency spectrum, matching both the resonant frequency of the genetic material and the operating frequency range of the medical treatment device can be reliable determined.
  • the inventors have found in a non-obvious way that the multi-stage shift of the basic resonant frequency and/or the one or more shifted resonant frequencies shifts the resonant frequencies in a reliable and accurate manner so to be suitable to be used to kill abnormal rapidly dividing tumor cells, or for treatment against non-healthy invading microorganism to break them down by specifically interacting with their DNA, RNA and/or mRNA.
  • This may be achieved by multi-shifting the resonant frequency so as to cause e.g.
  • elongating, stretching, mechanical shearing which may also be referred to as vortexing, or oxidizing, or for creating cell membrane charges, creating cell membrane stress leading into cellular profilation leading into an immune response, e.g. influencing e.g. mitogondrien by their double membrane or ATP (adenosine triphosphate) production and/or by training the organism’s defense cells, such as T-cells.
  • vortexing or oxidizing
  • cell membrane charges creating cell membrane stress leading into cellular profilation leading into an immune response, e.g. influencing e.g. mitogondrien by their double membrane or ATP (adenosine triphosphate) production and/or by training the organism’s defense cells, such as T-cells.
  • ATP adenosine triphosphate
  • the determined frequency is suitable to provide an electrical signal, e.g. an electrical current etc., for affecting, e.g. stressing, altering, breaking, destroying, etc., genetic material, such as DNA, RNA and/or mRNA, and/or proteins, cellular membranes, tissues, or the like, for therapeutic purposes, e.g. for resonance frequency therapy or the like. Since this enables a subject and/or the genetic material carried by the subject to be treated, the correspondingly generated output of a medical treatment device can also be referred to as an electroceutical.
  • an electrical signal e.g. an electrical current etc.
  • the genetic material may be affected or harmed by breaking down and/or reorganizing/modifying strands, etc.
  • This allows for attacking pathogens by attacking their DNA, RNA and/or mRNA in the blood cycle, so as to replace at least partially or in total antibiotics drugs by electronically initiated drugs called electroceuticals.
  • electroceuticals In other words, this allows for disturbing cells in a selective way, such as cancer cell eliminations of metastasis developments true blood or the interstitium, etc.
  • the medical treatment device can be controlled to create a micro-current, a modulated micro-current, i.e.
  • a so called bio-current, and/or a magnetic field to deliver the needed charges in the right form that affect DNA, RNA, mRNA, etc., sequencing, transcoding and forming proteins, dividing cell viability or disturbing cell membrane viability of the organism, such as an animal and human life-form.
  • determining the resonant frequency as described herein may also be applied to sections of DNA, RNA and/or mRNA, as in genes, for example. Using genetic coding information, determining the resonant frequencies may also be utilized with other subcomponents of genetic material, such as the coding associated with enzymes, immune factors, oncogenes, oncogenic growth factors, and other proteins. In at least some embodiments, the resonant frequency may be determined using basic information about a protein, for example, how many amino acids are in the protein chain. Because an amino acid is typically coded by three bases in the messenger RNA, the number of bases for use in determining resonant frequency domains can be ascertained by multiplying the number of amino acids in a protein chain by 3. For example, if there are 100 amino acids in a protein chain, there would be 300 bases in the final messenger RNA related to that protein.
  • the spacing length may be derived from a suitable data source, such as a database, e.g. a scientific genome database, which may be publically or commercially available, e.g. as an online database.
  • a determining device and/or the medical treatment device may comprise a data interface configured to receive the spacing length from the data source. Additionally or alternatively, the length information may be stored in a memory, look-table, or the like, and may be received from the determining device and/or medical treatment device from there.
  • the length of at least substantially any object can be considered as having a resonant frequency by virtue of correlation with a wavelength that manifests itself into a surrounding tissue or medium.
  • the length of biomolecular chains of DNA, RNA and/or mRNA may be calculated, and thus may provide wavelength-matching information in vacuum unique to a specific length of strands of genetic material.
  • the entire length of a piece or section of genetic material may be determined by multiplying the number of base pairs or bases in the genetic material with the spacing length between base pairs or bases.
  • the DNA genome of the so-called Papillomavirus which contains 7.900 base pairs, which information may be derived from a suitable data source, as explained above.
  • the 7.900 base pairs are multiplied by the base pair spacing of 3,4 e-10 m (meters) total length of the genome.
  • the length of an object may represent the object's wavelength
  • the length of the Papillomavirus represents its wavelength of 2.686 nm or 2686 e- 9 m.
  • the base pair spacing may be determined using an, preferably simplified, Watson-Crick model of base pair spacing, and using a constant value.
  • the Watson-Crick model of base pair spacing is an average spacing over the entire length of the DNA molecule, since the base pair spacing in strands of DNA is not always consistent, but localized areas contain "squeezing" or “spreading” of base pairs in various ways, e.g. they may be turned around histones and pushed in chromosomes.
  • the Papillomavirus may also have parts of a z-helix with other distances between base-pairs.
  • the B-helix is the most common in-vivo DNA form in bacterial and eukaryotic life forms, and is used herein as illustration of the method described herein.
  • the base pair spacing length can be expressed as 3.4 e-10 m.
  • the method step of determining the basic resonant frequency of the genetic material by dividing the velocity through a tissue or medium surrounding the genetic material by the wavelength of the genetic material it is noted that the genetic material typically exists in a medium of living tissue, through which electromagnetic radiation propagates at a different speed than through a vacuum. That is, this velocity may be calculated or determined before. Accordingly, if the DNA under consideration was in a medium of vacuum, velocity would be the speed of electromagnetic radiation, or light, in the vacuum. For purposes of comparison, if the exemplary Papillomavirus was in a vacuum medium, the velocity of electromagnetic radiation through vacuum, which is
  • 299.792,458 m/s would be used in determining a basic resonant frequency through vacuum. Dividing this velocity, i.e. 299.792,458 m/s, by the Papillomavirus genome wavelength of 2686 nm or 2,686 e-6 m, the theoretical resonant frequency for the Papillomavirus in an vacuum medium is determined as 1 11 ,612 THz.
  • the average magnetic permeability p through in-vivo tissue is known to be the same as that in vacuum of 1 ,2566370614 e-6 H/m (henrys/meter (inductance)) and the electrical permittivity E is 71 e-12 F/m (farads/meter (capacitance)).
  • the velocity, i.e. v EM through the medium of living tissue can be calculated or determined as 114.127,662 m/s.
  • This in-vivo therapeutic resonant frequency determined for the exemplary Papillomavirus genome appears in the infrared range of the electromagnetic spectrum.
  • a resonant frequency of the genetic material may be understood as the increase in amplitude of the natural oscillation or frequency of a system, when exposed to a periodic force whose frequency is equal or very close to the natural frequency of the system.
  • the natural oscillation of a system or part of a system is defined as its natural resonant frequency.
  • the natural electromagnetic resonant frequencies for genomes fall for the most part in the infrared region of the electromagnetic spectrum.
  • the natural resonant frequencies for genes and smaller portions of DNA or RNA appear in the near infrared, visible, and near ultraviolet regions of the spectrum.
  • the natural resonant frequencies such as those associated with genomic material are not achievable due to the technical limitations of the device itself.
  • a system is able to store and transfer energy between two or more different storage modes, which is necessary for communication and exchange of information, and it may bound to certain molecules or ions by the combination of several contributing structures or it may break that bounding in different ways, as mechanical oscillations, e.g.
  • Vortex may be understood as a region in which the flow of applied energy and/or charges revolves around an axis line, which may be straight or curved.
  • a vortex may be regarded as a major component of turbulent energy and/or charge movement flow.
  • a key concept in the dynamics of a vortex is the vorticity, a vector that describes the local rotary motion at a point. In most vortices, there is a velocity change, the velocity is greatest next to its axis and decreases in inverse proportion to the distance from the axis. Once formed, vortices can move, stretch, twist, and interact in complex ways.
  • a moving vortex carries some angular and linear momentum, energy, and mass, with moments of high forces, like breaking the hydrogen bound between strands in the DNA), or charge modifications, etc. It is noted that, typically, in-vivo, in living organisms there is not only one resonance frequency but more a resonance spectrum that change over time depending of the health conditions of this organism, so that the term “frequency” as used herein may also refer to such resonance frequency spectrum, i.e. a frequency range and/or frequency domain.
  • the multi-stage shift on the basic resonant frequency may also be referred to as “vortex shift” utilizing the effect of “vortexing and vorticity”, which may be broadly understood as aiming on stressing and breaking the hydrogen bonding of pathogens.
  • vortex shift utilizing the effect of “vortexing and vorticity”, which may be broadly understood as aiming on stressing and breaking the hydrogen bonding of pathogens.
  • the lower octave of a therapeutic resonant frequency domain may have a longer wavelength domain
  • the higher octave of a therapeutic resonant frequency domain may have a shorter wavelength.
  • the lower wavelength domain has less energy to transfer than the higher wavelength domain, but both still resonate with the basic resonant frequency domain.
  • coming closer with the shifted frequency to the basic or original resonant frequency domain may result in higher energy or electrical charge to be delivered to an organism comprising the genetic material, and getting further away from the basic or original resonant frequency domain may result in lower energy or electrical charge to be delivered to the organism, taking a longer time to achieve a corresponding result compared with the higher energy delivery.
  • the medical treatment device may be applied to a subject carrying the genetic material to be affected, harmed, or the like.
  • the subject may be infested or infected by the pathogen, microorganism, etc., which is to be weakened, damaged or destroyed by excitation of the electrical signal matching its resonant frequency.
  • the subject may be a living human, an animal, or may be provided in-vitro, e.g. in a Petri dish, or the like.
  • the subject may be infested or infected by the pathogen, microorganism, etc., which is to be weakened, damaged or destroyed by excitation of its resonant frequency.
  • determining the one or more shifted resonant frequencies may comprise performing a first multiplication or division operation on the basic resonant frequency using a first factor to obtain a first shifted resonant frequency, and then performing multiple further multiplication or division operations to obtain further shifted resonant frequencies, wherein each operation uses a factor different to each of the others and each operation applies the corresponding factor to the shifted resonant frequency obtained from the preceding multiplication or division operation, as many times as necessary, until at least two shifted resonant frequencies are determined to be in the operable frequency range that can be output by the medical treatment device. It is noted that this may be device-depended, wherein the highest range ad device can be emitted, e.g.
  • the limit of a device’s channel may be e.g. 300 MHz, or the like.
  • the basic resonant frequency may be divided by the factor of first 2, then divide this result by the factor 4, then divide this result by the factor 8, then divide this 7 and then divide this result by the factor 5, in a repetitive way, as many times as necessary, to reach a frequency in the medical treatment device's operable range of the micro current or magnetic field ranges.
  • a first one of the shifted resonant frequencies may be determined to be as close as possible to an upper limit of the operable frequency range, thereby forming a primary frequency domain.
  • the primary frequency domain may be used to provide the corresponding driving signal and/or electrical signal to a first applicator, e.g. a pair of electrodes, configured to be applied to the subject, i.e. the organism, to be treated.
  • a first applicator e.g. a pair of electrodes
  • multi-frequency treatment may be applied to the subject by using a frequency that matches both the resonant frequency of the genetic material and the operable range of the medical treatment device.
  • a second one of the shifted resonant frequencies may be determined to be as close as possible to an upper limit of the operable frequency range but lower than the determined primary frequency domain, thereby forming a secondary frequency domain.
  • the second frequency domain may be used to provide the corresponding driving signal and/or electrical signal to a second applicator, e.g. a pair of electrodes, configured to be applied to the subject, i.e. the organism, to be treated.
  • a second applicator e.g. a pair of electrodes
  • multi-frequency treatment may be applied to the subject by using a frequency that matches both the resonant frequency of the genetic material and the operable range of the medical treatment device.
  • the factors different to each of the others may comprise 2, 4, 8, 7 and 5, applied in the given order or reverse order.
  • the inventors have found in a non-obvious way that these factors result in a resonant frequency that is harmful to the genetic material in particularly reliable an effective way. It has been shown in experiments and simulations that these factors can shift the basic resonant frequency, and likewise the subsequently determined one or more shifted resonant frequencies into the operable range of the medical treatment device while maintaining the vortexing effect.
  • the factors different to each of the others may be cycled in the given order or reverse order, and wherein factor 2 is used as the first factor and the others as the respective subsequent factor and is applied to the respective shifted resonant frequency obtained as a result from the preceding operation.
  • the factors 2, 4, 8, 7 and 5 may cycled in the given order or reverse order. This results in determining the one or more shifted resonant frequencies within the operable range of the medical treatment device while maintaining the vortexing effect on the genetic material.
  • performing the multiple further multiplication or division operations comprises cycling the factors different to each of the others in a repetitive manner.
  • any of factors 2, 4, 8, 7, and 5 as described above can form the starting point.
  • it may be chosen whether to start with 2, 4, 8, 7 or 5, e.g. to start with 5, then 4, then 7, etc., or in a different order and/or starting point.
  • Each factor may be applied once initially, and then, if the operable frequency range termination criterion has not yet been reached, some or all of the factors may be applied again until the shift in the base resonant frequency becomes larger and larger and is within the operable frequency range. This results in determining the one or more shifted resonant frequencies within the operable range of the medical treatment device while maintaining the vortexing effect.
  • a refractive index (n) may be given by the ratio of the speed of electronic signaling in a vacuum to the speed of electronic signaling in the tissue or medium under consideration that surrounds the genetic material.
  • determining the velocity through the tissue or medium surrounding the genetic material comprises a temperature compensation with respect to a reference temperature.
  • the basic resonant frequency, and likewise the one or more shifted resonant frequencies may be determined at a reference temperature, e.g. 37° C which is not limited herein, wherein temperature changes should be corrected to conductivity changes, which changes also the velocity of electromagnetic radiation through the tissue or medium surrounding the genetic material.
  • a reference temperature e.g. 37° C which is not limited herein
  • conductivity of an electrolyte generally increases for each degree rise in temperature. With increase in temperature the viscosity of the solvent decreases and pH is moving up and thus ions can move faster. In case of weak electrolyte as in tissues, when the temperature is increased its degree of dissociation increases, thus conductivity increases.
  • conductance sigma may be determined as 0,41 S/m (Siemens per meter), for example between 0,32 S/m and 0,52 S/m. Conductance sigma increases continuously and uniformly. Maximum conductance sigma with 0,79 S/m, for example between 0.7 S/m; 0.87 S/m, can be reached at 80 degrees Celsius. The change of temperature can be assumed as being linear from about 20° C to about 80° C.
  • the velocity of electromagnetic radiation through the tissue or medium surrounding the genetic material i.e.
  • v EM can be determined by dividing or multiplying the velocity as determined above by a temperature compensation value.
  • the method described herein can be used to correlate with any medium surrounding the genetic material under consideration, as long as an accurate velocity of electromagnetic radiation through the tissue or medium is known or can be determined.
  • a deviation from the reference temperature is considered by multiplying or dividing the velocity through the tissue or medium surrounding the genetic material by a temperature compensation factor.
  • the temperature compensation factor is 0,023255581 degree Celsius (° C).
  • This temperature compensation factor may be applied to compensate a difference of temperature between the actual temperature of the tissue or medium surrounding the genetic material and the reference temperature, which may be e.g. 37° C per degree Celsius (° C).
  • the velocity of electromagnetic radiation i.e. V E M
  • V E M may be temperature compensated by multiplying (or dividing) the velocity determined as described above, i.e.
  • the reference temperature is 37° C. It has been shown in experiments and simulations that this reference temperature applies to a wide range of tissues or mediums surrounding the genetic material, allowing the basic resonant frequency, and likewise the one or more shifted resonant frequencies, to be determined more accurately.
  • the one or more shifted resonant frequencies may be compensated depending on a specified treatment by multiplying or dividing by at least one treatment compensation factor. It has been shown in experiments and simulations that the resonant frequency may vary depending on which part of the subject is attacked by the genetic material, i.e. the pathogen, microorganism, etc. In this way, a wide range of diseases may be treated using a suitable resonant frequency, i.e. a disease-specific resonant frequency.
  • the specified treatment is selected from at least psychological disease treatment and physical disease treatment. It has been shown in experiments and simulations that the optimum resonant frequency may vary depending on whether it is an at least primarily psychological disease or an at least primarily physical disease. In this way, a wide range of diseases may be treated using a suitable resonant frequency, i.e. a diseasespecific resonant frequency.
  • the treatment compensation factor is first 3 and then 6 or only one of 3 and 6, if the specified treatment is psychological disease treatment. It has been shown in experiments and simulations depending on currents of magnetic fields in use that these treatment compensation factors allow to determine a more effective resonant frequency to specific diseases and/or pathogens, microorganisms, etc.
  • the compensation factor is applied in a repetitive way. This allows to determine a wider range of suitable resonant frequencies.
  • the treatment compensation factor is 9, if the specified treatment is physical disease treatment. It has been shown in experiments and simulations that this treatment compensation factor depending on currents or magnetic fields in use, allow to determine a more effective resonant frequency to specific diseases and/or pathogens, microorganisms, etc.
  • the treatment compensation factor is between or equal to 11 and 11 ,25, if the specified treatment is physical disease treatment. It has been shown in experiments and simulations that this treatment compensation factor allow to determine a more effective resonant frequency to specific diseases and/or pathogens, microorganisms, etc.
  • the method may further comprise determining an electrical charge delivered, or estimated to be delivered, during treatment by applying for non-sinusoidal waveforms a Fourier analyzes to the basic resonant frequency and/or a specific one of the one or more shifted resonant frequencies. Based on a result of the Fourier analyzes, which may be fed back for evaluation, the delivery of electric charge determined for the specific basic resonant frequency and/or shifted resonant frequency may be compared with a desired electrical charge to be delivered. If the desired electrical charge cannot be achieved by applying the determined resonant frequency, it may be varied by selecting another one of the one or more shifted resonant frequencies in order to at least coming closer to the desired electrical charge to be delivered.
  • the electric behavior and electrical charge sensitivity allows for interacting, stimulating of retracting electrons and ions from DNA, RNA, proteins, and cells, so that affecting or harming the genetic material is more effective if applying the desired charge known or at least expected, due to e.g. estimation, simulation etc. of the effects on the genetic material, to be suitable for treatment.
  • the Fourier analysis may be utilized to determine the proper frequency domains at which DNA, RNA and proteins and cell membranes will still react with the smallest side effects by adjusting and delivering the proper electric charges, e.g. measured in coulomb, to break or disrupt the hydrogen bound in pathogens and/or disturb in cell membranes the membrane transport.
  • a result of the Fourier analyzes may be used to determine whether or not the electrical charge corresponding to a specific one of the basic resonant frequency and/or the one or more shifted resonant frequencies deviates from a desired electrical charge to be delivered, and wherein the Fourier analyzes is applied to one or more other specific ones of the one or more shifted resonant frequencies until it is determined that the respective specific one resonant frequency results in delivering the desired accumulated electrical charge, at least within a tolerance range.
  • the resonant frequency can be determined more accurately, particularly for disease-specific treatment.
  • a determining device or apparatus for providing at least information about an electrical signal in correspondence with a resonant frequency range of genetic material by a medical treatment device.
  • the device comprises a processor that is configured to: receive length information data associated with a wavelength of the genetic material; determine a basic resonant frequency of the genetic material by dividing a velocity through a tissue or medium surrounding the genetic material by the wavelength of the genetic material; perform a multi-stage shift on the basic resonant frequency to an operable frequency range that can be output by the medical treatment device by applying multiple multiplication or division operations on the basic resonant frequency using a number of factors different to each other to obtain one or more shifted resonant frequencies determined to be in the operable frequency range; and provide at least information about a driver signal for providing the electrical signal based on the one or more shifted resonant frequencies determined to be in the operable frequency range.
  • the determining device may be connected to or may be part of the medical treatment device, particularly of the medical treatment device according to the third aspect. Further, the determining device may be configured to carry out the method described above with reference to the first aspect. By way of example, the determining device may be configured to carry out, e.g. by using its processor, a computer program element having stored computer instructions corresponding to the method steps as explained above. The determining device and/or the processor may be implemented in a single computing device or may be distributed over several computing devices. The determining device may further comprise a memory to interact with the processor, and one or more data interfaces configured to receive and or transmit data, such as the length information data, calculations or determinations, such as the multi-stage shift and the information about the driver signal, etc.
  • a medical treatment device or system comprising: an electrical signal generator; an applicator to be applied to a to-be-treated subject; and a determining device according to claim 20; wherein the electrical signal generator is configured to generate an electrical signal in accordance with a driver signal provided by the determining device; and wherein the applicator is configured to apply the generated electrical signal to the subject.
  • a computer program element which when executed by a processor is configured to carry out the method according to the first aspect, and/or to control a device according to the second aspect, and/or to control a treatment device according to the third aspect.
  • a computer-readable storage or transmission medium which has stored or which carries the computer program element according to the fourth aspect.
  • the same advantages can be achieved as explained above with respect to the first, second, third and/or fourth aspect.
  • the above embodiments may be combined with each other irrespective of the aspect involved. Accordingly, the method may be combined with structural features of the device and/or system of the other aspects and, likewise, the device and the system may be combined with features of each other, and may also be combined with features described above with regard to the method.
  • Fig. 1 shows a medical treatment device according to an embodiment.
  • Fig. 2 shows in a block diagram a controller of a medical treatment device, according to an embodiment.
  • Fig. 3 shows in a flow chart a method for providing an electrical signal in correspondence with a resonant frequency range of genetic material, according to an embodiment.
  • Fig. 1 shows a medical treatment device 100 for providing electrically induced treatment to a subject, and particularly for providing an electrical signal in correspondence with a resonant frequency range of genetic material.
  • the provided electrical signal is generated in correspondence with the resonant frequency of genetic material, which may be of a pathogen, microorganism, or the like, and is suitable for affecting, e.g. stressing, altering, breaking, destroying, etc., the genetic material, such as DNA, RNA and/or mRNA, and/or proteins, cellular membranes, tissues, or the like, for therapeutic purposes, e.g. for resonance frequency therapy etc.
  • the medical treatment device 100 comprises a housing 110, a controller 120 or, alternatively, is connected to the controller 120, which may also be referred to as a determining device or apparatus, a number of electrical signal generators 130, and a number of applicators 140. Further, optionally, the medical treatment device 100 may comprise a console 150, which may also be referred to as an operator console. Further optionally, the medical treatment device 100 may further comprise a service console.
  • an individual one of the number of electrical signal generators 130 corresponds to at least one channel of the medical treatment device 100. It is noted that one individual of the number of electrical signal generators 130 itself may comprise one or more channels, so that even with a single electrical signal generator 130 two or more separately controllable channels may be provided.
  • the housing 110 is, for example, formed as e.g. a rack and comprises a number of compartments.
  • some or all of the number of compartments is of same size, i.e. of same dimension, and of a same shape, so as to provide a modular platform.
  • each of the compartments is configured to accommodate a computing board or card, i.e. an individual one of the number of electrical signal generators 130.
  • the housing may accommodate the controller 120, as indicated by the corresponding reference sign in Fig. 1 .
  • Each of the number of electrical signal generators 130 which may also be referred to as number of electrical drivers, is provided on or as a computing board or card, which may be selectively inserted into one of the number of compartments. When inserted into the corresponding compartment, the respective electrical signal generator 130 is operatively connected to the controller 120, so that the controller 120 has the overall control. Further, the number of electrical signal generators 130 is configured to provide the electrically induced treatment, the method of which is provided in accordance with a type of the electrical signal generator or electrical driver 130.
  • the type of electrical signal generator 130 may be selected from an electric current driver, a current-controlled magnetic field driver, a voltage- controlled magnetic field driver, a led light driver, a halogen light driver, and an ultrasonic driver. Accordingly, the medical treatment device 100 may be freely configured, by utilizing, i.e. operating, one or more of these types of electrical signal generator or electrical driver 130 within the same medical treatment device 100.
  • the controller 120 i.e. the determining device or apparatus, comprises one or more of a memory, a processor, a data interface, a communication interface, etc., and is configured to receive length information data associated with a wavelength of the genetic material. It is further configured to determine a basic resonant frequency of the genetic material by dividing a velocity through a tissue or medium surrounding the genetic material by the wavelength of the genetic material. Further, the controller 120 is configured to perform a multi-stage shift on the basic resonant frequency to an operable frequency range that can be output by the medical treatment device by applying multiple multiplication or division operations on the basic resonant frequency using a number of factors different to each other to obtain one or more shifted resonant frequencies determined to be in the operable frequency range. Further, the controller 120 is configured to generate a driver signal for providing the electrical signal based on the one or more shifted resonant frequencies determined to be in the operable frequency range.
  • the controller 120 is configured to control, via the corresponding channel, the number of electrical signal generator or electrical drivers 130 based on a control program, which is only illustratively represented in Fig. 1 within the console 150, particularly within a graphical user interface. It is noted that the control program may alternatively or additionally be created and/or edited by using a separate software application that may be run on a separate computing device, such as workstation or the like.
  • the control program comprises a number of channel-specific driver signal description modules, wherein the driver signal is determined, generated and/or provided by the controller 120 to be based on the one or more shifted resonant frequencies determined to be in the operable frequency range, as explained above.
  • the control program and/or the number of channel-specific driver signal description modules may comprise one or more signal parameters that comprise one or more of a signal shape or waveform, amplitude, frequency, and signal duration.
  • These signal parameters may define a specific signal shape or waveform, which may also comprise one or more sequences of specific signal shapes or waveforms and/or one or more combinations of signal shapes or waveforms.
  • the specific signal shape or waveform may be sine, half sine, saw-tooth, triangle, line, DC, square, pulse, sine-segment, trapezoidal segment, Gaussian distribution, ECG, an arbitrary waveform, or the like.
  • the medical device may be configured to vary one or more parameters of the specific signal shape or waveform, such as duration, frequency, phase, duty cycle, pulse and/or amplitude. It is noted that the driver signal description module of a first one of the number of channels may differ in some or all signal parameters from a second one of the number of channels, etc.
  • Fig. 1 illustrates for reasons of clarity exactly two applicators, but this is not limited herein as described below.
  • the number of applicators 140 is operatively connected to the number of electrical signal generator or electrical drivers 130, wherein the number of applicators 140 is equal or greater than the number of electric drivers 130.
  • each channel may comprise one or more applicators 140, optionally comprising at least one pair of applicators 140 per channel.
  • the number of applicators 140 is configured to e.g. be brought into contact with the subject, to apply a specific electric current to the subject, e.g.
  • the type of applicator 140 may be selected in accordance with the selected type of electric generator 130 for the corresponding channel.
  • the number of applicators 140 may be provided, also pair-wise, as a skin electrode, a head electrode, which can optionally be arranged in a kind of helmet, a coil, a needle, which may be used on the skin and/or dermis, epidermis or hypodermis, a lighting device, and/or an ultrasonic probe.
  • the number of applicators 140 may be configured to provide the method of treatment corresponding to the type of electrical signal generator 130 of the corresponding channel.
  • an electric current generator may be operated by using one or more electrodes
  • a magnetic field driver may be operated by using one or more coils
  • a led light driver a halogen light driver
  • an ultrasonic driver may be operated by using one or more electrodes etc.
  • Fig. 2 shows in a block diagram the controller 120, particularly in terms of its functionality as a determining device or apparatus for providing an electrical signal in correspondence with a resonant frequency range of genetic material by using the medical treatment device 100, and particularly at least one of its electric signal generators 130 and/or one or more of its applicators 140.
  • the controller 120 may be part of the medical treatment device 100 or may be arranged separately and connected to the medical treatment device 100.
  • the controller 120 comprises at least one data processor 121 , which may also be implemented by an FPGA, a microcontroller, etc., wherein two or more processors may be utilized, even in a distributed manner. It is noted that the processor 121 may execute a computer program, so as to be configured in a manner as described below.
  • the controller 120 is configured to receive length information data associated with or indicating a wavelength of the genetic material.
  • the length information data is received from a suitable data source 200, such as a database, e.g. a genome database, a look-up table, or the like, configured to provide the length information in electronic form.
  • the data source may be connected to the controller 120, as exemplarily shown in Fig. 2, and may be part of the medical treatment device 100, e.g. if the length information is stored internally in a memory as a look-up table, or the like, or may be arranged separately, e.g. if the data source is a remote database, such as a genome database, or the like.
  • the controller 120 and particularly the processor 121 , may be configured to determine, e.g. calculate the length information data based on information about a number of base pairs or bases of the genetic material and knowledge that one complete turn of a helix of the genetic material spans a distance of 35,4 angstroms, i.e. 0,340 nm, on its axis.
  • the controller 120 and particularly the processor 121 , is configured to determine a basic resonant frequency of the genetic material by dividing a velocity v EM through a tissue or medium surrounding the genetic material by the wavelength A, i.e. the total length described vEM above, of the genetic material.
  • controller 120 and particularly the processor 121 , is configured to perform, e.g. calculate, etc., a multi-stage shift on the basic resonant frequency to an operable frequency range that can be output by the medical treatment device 100.
  • information about the operable frequency range may be available from specification, such as a data sheet etc., and also in electronic form, e.g. as a look-up, etc.
  • the multi-stage shift on the basic resonant frequency is performed by applying multiple multiplication or division operations on the basic resonant frequency and, gradually to the resulting shifted resonant frequencies, using a number of factors different to each other to obtain one or more shifted resonant frequencies determined to be in the operable frequency range of the medical treatment device 100, and particularly in the operable frequency range of at least one of its electric signal generators 130 and/or one or more of its applicators 140.
  • the factors different to each of the others may comprise 2, 4, 8, 7 and 5, applied in the given order or in reverse order, or in a different order choosing any of the factors as a starting point.
  • the factors different to each of the others may be, also repeatedly, cycled in the given order or reverse order.
  • factor 2 is used as the first factor and the others as the respective subsequent factor and is applied to the respective shifted resonant frequency obtained as a result from the preceding operation.
  • performing the multiple further multiplication or division operations may comprise cycling the factors different to each of the others in a repetitive manner. For example, taking any starting point in the series of factors 2, 4, 8, 7, and 5 as described above, starting with e.g. factor 2, or any other factor, applied to the base resonant frequency, then e.g. factor 4, or any other factor, applied to the result thereof, i.e. the factor-2-operation, then e.g.
  • the medical treatment device may comprise at least two separated, different channels.
  • the operable range of a first channel may be limited to 300 MHz and the operable range of a second channel may be limited to 150 MHz, wherein these frequencies or limits of the operable range are indicated only for illustrative purposes and are not limited herein, and other frequency limits may be given by the medical treatment device.
  • the frequency for the first channel may be determined as described above, i.e. by one or more of the division or multiplication operations.
  • the determined frequency, frequencies, and/or frequency range may form a carrier wave signal, referred to domain 1 .
  • the same is performed for the second channel, wherein the determined frequency, frequencies, and/or frequency range, is required to be within the operable range of the second channel, and, as an additional condition, to be lower than domain 1.
  • the second domain is in row of the determined first domain. If the limits are not the same, the second domain is the first lower frequency of the first domain.
  • there may be determined a modulation frequency for each channel to be 11 to 11 ,25 times lower than the carrier wave, i.e. the first and/or second domain, both forming a frequency domain.
  • controller 120 and particularly the processor 121 , is configured to provide at least information about a driver signal for providing the electrical signal based on the one or more shifted resonant frequencies determined to be in the operable frequency range.
  • the one or more shifted resonant frequencies determined to be in the operable frequency range may be used to describe and/or generate the driver signal, which may drive the number of electric signal generators 130 to provide the output for treatment, via the number of applicators 140.
  • the controller 120 and particularly the processor 121 , is configured to determine a first one of the shifted resonant frequencies which has to be as close as possible to an upper limit of the operable frequency range, thereby forming a primary frequency domain.
  • the primary frequency domain may be used to provide the corresponding driving signal and/or electrical signal to a first applicator, e.g. a pair of electrodes, configured to be applied to the subject, i.e. the organism, to be treated.
  • the controller 120 and particularly the processor 121 , is configured to determine a second one of the shifted resonant frequencies which has to be as close as possible to an upper limit of the operable frequency range but lower than the determined primary frequency domain, thereby forming a secondary frequency domain.
  • the second frequency domain may be used to provide the corresponding driving signal and/or electrical signal to a second applicator, e.g. a pair of electrodes, configured to be applied to the subject, i.e. the organism, to be treated.
  • a second applicator e.g. a pair of electrodes
  • multi-frequency treatment may be applied to the subject by using a frequency that matches both the resonant frequency of the genetic material and the operable range of the medical treatment device.
  • the controller 120 and particularly the processor 121 , is configured to determine the velocity through the tissue or medium surrounding the genetic material utilizing a temperature compensation with respect to a reference temperature, e.g. 37° C.
  • the controller 120 and particularly the processor 121 , is configured to compensate the one or more shifted resonant frequencies depending on a specified treatment by multiplying or dividing by at least one treatment compensation factor.
  • the specified treatment is selected from at least psychological disease treatment and physical disease treatment.
  • the treatment compensation factor is first 3 and then 6 or only one of 3 and 6, preferably depending on currents or magnetic fields in use, if the specified treatment is psychological disease treatment.
  • a second one of the one or more shifted resonant frequencies e.g.
  • the treatment compensation factor is 9, if the specified treatment is physical disease treatment.
  • the treatment compensation factor is between or equal to 11 and 11 ,25, if the specified treatment is physical disease treatment. Further optionally, the compensation factor is applied in a repetitive way.
  • the controller 120 and particularly the processor 121 , is configured to determine an electrical charge to be delivered, or estimated to be delivered, during treatment by e.g. applying a Fourier analyzes to the basic resonant frequency and/or a specific one of the one or more shifted resonant frequencies. This may be performed prior to generating and/or providing the driver signal and/or may be performed during operation of the medical treatment device 100. Based on a result of the Fourier analyzes, which may be fed back for evaluation, the delivery of electric charge determined for the specific basic resonant frequency and/or shifted resonant frequency may be compared with a desired electrical charge to be delivered.
  • the desired electrical charge cannot be achieved by applying the determined resonant frequency, it may be varied by selecting another one of the one or more shifted resonant frequencies in order to at least coming closer to the desired electrical charge to be delivered.
  • a result of the Fourier analyzes may be used to determine whether or not the electrical charge corresponding to a specific one of the basic resonant frequency and/or the one or more shifted resonant frequencies deviates from a desired electrical charge to be delivered, and wherein the Fourier analyzes is applied to one or more other specific ones of the one or more shifted resonant frequencies until it is determined that the respective specific one resonant frequency results in delivering the desired accumulated electrical charge, at least within a tolerance range.
  • the controller 120 and particularly the processor 121 may be configured to receive measurement data indicating the electrical charge to be delivered or delivered, which measurement data may be obtained during operation of the medical treatment device 100.
  • the controller 120 and particularly the processor 121 may be configured to determine, e.g. calculate, the electric charge delivered or estimated to be delivered, by e.g. using knowledge of the driver signal generated based on the specific one of the basic resonant frequency and/or the one or more shifted resonant frequencies.
  • Fig. 3 shows in flow chart a method 300 for providing an electrical signal in correspondence with a resonant frequency range of genetic material by the medical treatment device 100.
  • the method is preferably carried out by the medical treatment device 100 and/or the controller 120, and/or its processor 121 , as described above, and optionally utilizes the data source 200 as described above.
  • the method comprises receiving length information data associated with a wavelength of the genetic material.
  • the length information data may be obtained from the data source 200, or may be stored locally, or may be calculated based on further knowledge about the genetic material.
  • the method comprises determining a basic resonant frequency of the genetic material by dividing a velocity through a tissue or medium surrounding the genetic material by the wavelength of the genetic material.
  • the method comprises performing a multi-stage shift on the basic resonant frequency to an operable frequency range that can be output by the medical treatment device by applying multiple multiplication or division operations on the basic resonant frequency using a number of factors different to each other to obtain one or more shifted resonant frequencies determined to be in the operable frequency range.
  • the factors different to each of the others may comprise 2, 4, 8, 7 and 5, applied in the given order or in reverse order.
  • the factors different to each of the others may be, also repeatedly, cycled in the given order or reverse order.
  • the method comprises generating at least information about a driver signal for providing the electrical signal based on the one or more shifted resonant frequencies determined to be in the operable frequency range.
  • performing the multi-stage shift comprises determining the one or more shifted resonant frequencies by performing a first multiplication or division operation on the basic resonant frequency using a first factor to obtain a first shifted resonant frequency, and then performing multiple further multiplication or division operations to obtain further shifted resonant frequencies, wherein each operation uses a factor different to each of the others and each operation applies the corresponding factor to the shifted resonant frequency obtained from the preceding multiplication or division operation, as many times as necessary, until at least two shifted resonant frequencies are determined to be in the operable frequency range that can be output by the medical treatment device.
  • a first one of the shifted resonant frequencies is determined to be as close as possible to an upper limit of the operable frequency range, thereby forming a primary frequency domain.
  • a second one of the shifted resonant frequencies is determined to be as close as possible to an upper limit of the operable frequency range but lower than the determined primary frequency domain, thereby forming a secondary frequency domain.
  • the method comprises determining the velocity through the tissue or medium surrounding the genetic material by utilizing a temperature compensation with respect to a reference temperature, e.g. 37° C.
  • the method comprises compensating the one or more shifted resonant frequencies depending on a specified treatment by multiplying or dividing by at least one treatment compensation factor, depending on currents or magnetic fields in use.
  • the specified treatment is selected from at least psychological disease treatment and physical disease treatment.
  • the treatment compensation factor is first 3 and then 6 or only one of 3 and 6, if the specified treatment is psychological disease treatment.
  • the treatment compensation factor is 9, if the specified treatment is physical disease treatment.
  • the treatment compensation factor is between or equal to 11 and 11 ,25, if the specified treatment is physical disease treatment.
  • the compensation factor is applied in a repetitive way.
  • the method comprises determining an electrical charge to be delivered, or estimated to be delivered, during treatment by e.g. applying a Fourier analyzes to the basic resonant frequency and/or a specific one of the one or more shifted resonant frequencies. This may be performed prior to generating and/or providing the driver signal and/or may be performed during operation of the medical treatment device 100. Based on a result of the Fourier analyzes, which may be fed back for evaluation, the delivery of electric charge determined for the specific basic resonant frequency and/or shifted resonant frequency may be compared with a desired electrical charge to be delivered.
  • the desired electrical charge cannot be achieved by applying the determined resonant frequency, it may be varied by selecting another one of the one or more shifted resonant frequencies in order to at least coming closer to the desired electrical charge to be delivered.
  • a result of the Fourier analyzes may be used to determine whether or not the electrical charge corresponding to a specific one of the basic resonant frequency and/or the one or more shifted resonant frequencies deviates from a desired electrical charge to be delivered, and wherein the Fourier analyzes is applied to one or more other specific ones of the one or more shifted resonant frequencies until it is determined that the respective specific one resonant frequency results in delivering the desired accumulated electrical charge, at least within a tolerance range.
  • the controller 120 and particularly the processor 121 may be configured to receive measurement data indicating the electrical charge to be delivered or delivered, which measurement data may be obtained during operation of the medical treatment device 100.
  • the controller 120 and particularly the processor 121 may be configured to determine, e.g. calculate, the electric charge delivered or estimated to be delivered, by e.g. using knowledge of the driver signal generated based on the specific one of the basic resonant frequency and/or the one or more shifted resonant frequencies.
  • a computer program or computer program element is provided that is characterized by being configured to execute the method steps of the method according to one of the preceding embodiments, on an appropriate system.
  • the computer program element might therefore be stored on a data processing unit, which might also be part of an embodiment.
  • This data processing unit may be configured to perform or induce performing of the steps of the method described above. Moreover, it may be configured to operate the components of the above described device and/or system.
  • the computing unit can be configured to operate automatically and/or to execute the orders of a user.
  • a computer program may be loaded into a working memory of a data processor. The data processor may thus be equipped to carry out the method according to one of the preceding embodiments.
  • the computer program element might be able to provide all necessary steps to fulfill the procedure of an exemplary embodiment of the method as described above.
  • a computer readable medium such as a CD-ROM, USB stick or the like
  • the computer readable medium has a computer program element stored on it which computer program element is described by the preceding section.
  • a computer program may be stored and/or distributed on a suitable medium, such as an optical storage medium or a solid state medium supplied together with or as part of other hardware, but may also be distributed in other forms, such as via the internet or other wired or wireless telecommunication systems.
  • the computer program may also be presented over a network like the World Wide Web and can be downloaded into the working memory of a data processor from such a network.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé, un dispositif et/ou un système, et un élément de programme informatique permettant de fournir un signal électrique en correspondance avec une plage de fréquences de résonance de matériel génétique par un dispositif de traitement médical. Le procédé consiste à recevoir (S310), par un processeur (120, 121), des données d'informations de longueur associées à une longueur d'onde du matériau génétique. Le procédé consiste en outre à déterminer (S320), par le processeur (120, 121), une fréquence de résonance de base du matériau génétique par division d'une vitesse à travers un tissu ou milieu entourant le matériau génétique par la longueur d'onde du matériau génétique. En outre, le procédé consiste à réaliser (S330), par le processeur (120, 121), un décalage à étages multiples sur la fréquence de résonance de base vers une plage de fréquences utilisables qui peuvent être délivrées par le dispositif de traitement médical par application de multiples opérations de multiplication ou de division sur la fréquence de résonance de base à l'aide d'un certain nombre de facteurs différents les uns des autres pour obtenir une ou plusieurs fréquences de résonance décalées, déterminées comme étant dans la plage de fréquences utilisables. Et le procédé consiste à générer (S340) un signal de pilote servant à fournir le signal électrique sur la base de la ou des fréquences de résonance décalées déterminées comme étant dans la plage de fréquences utilisables.
PCT/EP2021/072537 2021-08-12 2021-08-12 Fourniture d'un signal électrique en correspondance avec une fréquence de résonance d'un matériau génétique WO2023016651A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/072537 WO2023016651A1 (fr) 2021-08-12 2021-08-12 Fourniture d'un signal électrique en correspondance avec une fréquence de résonance d'un matériau génétique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/072537 WO2023016651A1 (fr) 2021-08-12 2021-08-12 Fourniture d'un signal électrique en correspondance avec une fréquence de résonance d'un matériau génétique

Publications (1)

Publication Number Publication Date
WO2023016651A1 true WO2023016651A1 (fr) 2023-02-16

Family

ID=77520739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/072537 WO2023016651A1 (fr) 2021-08-12 2021-08-12 Fourniture d'un signal électrique en correspondance avec une fréquence de résonance d'un matériau génétique

Country Status (1)

Country Link
WO (1) WO2023016651A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015097A2 (fr) * 1998-09-11 2000-03-23 Berkshire Laboratories, Inc. Techniques d'utilisation de l'energie acoustique et/ou acousto-electromagnetique de resonance pour detecter et/ou exercer un effet sur des structures
US20070128590A1 (en) 2000-02-10 2007-06-07 Boehm Charlene A Methods for determining therapeutic resonant frequencies
US20100113983A1 (en) * 2008-10-31 2010-05-06 Microsoft Corporation Utilizing ultrasound to disrupt pathogens
WO2014006596A1 (fr) * 2012-07-06 2014-01-09 Pier Rubesa Appareil de création et d'émission d'ondes acoustiques capables d'influencer les propriétés fonctionnelles ou le comportement d'un système biologique tel qu'un être humain, un animal ou une plante
WO2018005031A1 (fr) * 2016-07-01 2018-01-04 Anapole Technolgies Inc. Traitement d'une maladie avec des champs électromagnétiques générant une résonance

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015097A2 (fr) * 1998-09-11 2000-03-23 Berkshire Laboratories, Inc. Techniques d'utilisation de l'energie acoustique et/ou acousto-electromagnetique de resonance pour detecter et/ou exercer un effet sur des structures
US20070128590A1 (en) 2000-02-10 2007-06-07 Boehm Charlene A Methods for determining therapeutic resonant frequencies
US20100113983A1 (en) * 2008-10-31 2010-05-06 Microsoft Corporation Utilizing ultrasound to disrupt pathogens
WO2014006596A1 (fr) * 2012-07-06 2014-01-09 Pier Rubesa Appareil de création et d'émission d'ondes acoustiques capables d'influencer les propriétés fonctionnelles ou le comportement d'un système biologique tel qu'un être humain, un animal ou une plante
WO2018005031A1 (fr) * 2016-07-01 2018-01-04 Anapole Technolgies Inc. Traitement d'une maladie avec des champs électromagnétiques générant une résonance

Similar Documents

Publication Publication Date Title
US10994133B2 (en) Methods for enhancing and modulating reversible and irreversible electroporation lesions by manipulating pulse waveforms
US11701161B2 (en) Optimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment
EP2994045B1 (fr) Appareil pour traiter une tumeur par un champ électrique alternatif et pour choisir une fréquence de traitement sur la base d'une taille cellulaire estimée
EP1740107B1 (fr) Dispositif de traitement electromagnetique
US7744524B2 (en) Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules
US9827437B2 (en) Skin treatment devices and methods
KR20090023544A (ko) 자립식 전자기 뇌표면 영역 치료 장치 및 그 이용 방법
US20230149708A1 (en) Tumor treating fields (ttf) for cancer treatment
US7280874B2 (en) Methods for determining therapeutic resonant frequencies
WO2023016651A1 (fr) Fourniture d'un signal électrique en correspondance avec une fréquence de résonance d'un matériau génétique
Markov Magnetic and electromagnetic field therapy: basic principles of application for pain relief
Dennis Inductively Coupled Electrical Stimulation-Part I: Overview and First Observations
Elson I. The little explored efficacy of magnetic fields in cancer treatment and postulation of the mechanism of action
Pilla An electrochemical consideration of electromagnetic bioeffects
Kim et al. Incorporation of reversible electroporation into electrolysis accelerates apoptosis for rat liver tissue
CN101432041B (zh) 用于增强伤口修复的电磁治疗设备及其使用方法
ZA200605544B (en) Electromagnetic treatment apparatus and method
JP2006340669A (ja) 細胞刺激装置
US20230301790A1 (en) Smart platform bioprinting bed with at least one controllable stimulator
Blank et al. Low-frequency electromagnetic fields evoke the stress response: mechanism of interaction with DNA and biomedical applications
WO2022233387A1 (fr) Dispositif de traitement médical actionnable par canal
CN106163614B (zh) 用于修复和再生心脏组织和用于心脏的电生理、代谢优化的装置和方法
KR20070015908A (ko) 전자기적 치료 장치 및 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21762448

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE